Bioinorganic Chemistry - Lab 83

05/04/2024

Lorenzo Verderi is the new PhD student working in Bioinorganic Chemistry - Lab 83 and supervising the activities of the lab! Good luck Lorenzo! Lorenzo Verderi

05/04/2024

Interested to know more about Ga(III) and In(III) complexes with biological properties? Check this work by Lorenzo Verderi , Mirco Scaccaglia , Silvana Pinelli , Giorgio Pelosi and Franco Bisceglie !

The aim of this work is to explore a new library of coordination compounds for medicinal applications. Gallium is known for its various applications in this field. Presently, indium is not particularly important in medicine, but it shares a lot of chemical traits with its above-mentioned lighter com...

05/04/2024

New arrival at the lab! A big welcome to Diego Dallatomasina and best of luck with your work on thiosemicarbazones with antiprotozoal activity!

10/07/2022

Another interesting piece of work leading to the role of Ru(II) complexes as antitumor agents triggered by light! Thanks to MDPI, Franco Bisceglie, Giorgio Pelosi, Marianna Pioli, Nicolò Orsoni, Silvana Pinelli at Bioinorganic Chemistry - Lab 83and all the other coauthors!

We report the synthesis and characterization of three half-sandwich Ru(II) arene complexes [(η6-arene)Ru(N,N′)L][PF6]2 containing arene = p-cymene, N,N′ = bipyridine, and L = pyridine meta- with methylenenaphthalimide (C1), methylene(nitro)naphthalimide (C2), or methylene(piperidinyl...

10/06/2022

Interested in how Bi complexes restore sensitivity in resistant bacteria? Take a look at our paper!
https://www.sciencedirect.com/science/article/pii/S0162013422001763?dgcid=author

Many thanks to all the authors who contributed to this interesting piece of work from the Bioinorganic Chemistry - Lab 83! Mirco Scaccaglia Martina Rega Dario Dax Giovanardi Giorgio Pelosi Silvana Pinelli and Franco Bisceglie

Resistant bacteria represent an urgent worldwide threat. NDM-1-producing strains are rendering the last line antibiotics less effective. Six bismuth c…

23/05/2022

Interested in what Copper can do towards thiosemicarbazones, BSA, DNA and leukemic cells? A new agile work from Bioinorganic Chemistry - Lab 83 with the contribution of Giorgio Pelosi Silvana Pinelli and Franco Bisceglie just published on Compounds.

Some ten million cancer deaths occurred in 2020, highlighting the fact that the search for new anticancer drugs remains extremely topical. In the search for new coordination compounds with relevant biological properties, the choice of a metal ion is important for the design of the complex. In this r...

06/10/2021

BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2021 Nobel Prize in Chemistry to Benjamin List and David W.C. MacMillan “for the development of asymmetric organocatalysis.”

Building molecules is a difficult art. Benjamin List and David MacMillan are awarded the Nobel Prize in Chemistry 2021 for their development of a precise new tool for molecular construction: organocatalysis. This has had a great impact on pharmaceutical research, and has made chemistry greener.

Many research areas and industries are dependent on chemists’ ability to construct molecules that can form elastic and durable materials, store energy in batteries or inhibit the progression of diseases. This work requires catalysts, which are substances that control and accelerate chemical reactions, without becoming part of the final product. For example, catalysts in cars transform toxic substances in exhaust fumes to harmless molecules. Our bodies also contain thousands of catalysts in the form of enzymes, which chisel out the molecules necessary for life.

Catalysts are thus fundamental tools for chemists, but researchers long believed that there were, in principle, just two types of catalysts available: metals and enzymes. Benjamin List and David MacMillan are awarded the Nobel Prize in Chemistry 2021 because in 2000 they, independent of each other, developed a third type of catalysis. It is called asymmetric organocatalysis and builds upon small organic molecules.

The rapid expansion in the use of organic catalysts is primarily due to their ability to drive asymmetric catalysis. When molecules are being built, situations often occur where two different molecules can form, which – just like our hands – are each other’s mirror image. Chemists will often only want one of these, particularly when producing pharmaceuticals.

Organocatalysis has developed at an astounding speed since 2000. Benjamin List and David MacMillan remain leaders in the field, and have shown that organic catalysts can be used to drive multitudes of chemical reactions. Using these reactions, researchers can now more efficiently construct anything from new pharmaceuticals to molecules that can capture light in solar cells. In this way, organocatalysts are bringing the greatest benefit to humankind.

Learn more
Press release: https://bit.ly/3nALTUp
Popular information: https://bit.ly/3nAM0PP
Advanced information: https://bit.ly/3tJb2NA

16/03/2021

26/02/2021

A new work from Bioinorganic Chemistry - Lab 83 Franco Bisceglie Marianna Pioli Nicolò Orsoni Mirco Scaccaglia Silvana Pinelli Giorgio Pelosi

The synthesis, photoactivation and biological activity of a new piano-stool Ru(II) complex is herein reported. The peculiarity of this complex is that its monodentate ligand which undergoes the photodissociation is an asymmetric bis-thiocarbohydrazone ligand that possesses a pyridine moiety binding....

04/02/2021

Today is : Platinum-based compounds are amongst the drugs used to treat cancer; here's a look at how they work in : https://cen.acs.org/pharmaceuticals/oncology/Periodic-graphics-Platinum-Drugs-Cancer/96/i37

11/10/2020